ESR1 and luminal B breast carcinoma: ESR1 fusions were identified in more aggressive forms of breast cancer (ET resistant MBC and Luminal B breast cancer) and can guide the diagnosis and the development of therapeutic strategies to treat a subset of patients with tumors that harbor these ESR1 alterations.